Navigation Links
Ceragenix Compound Shows Promise for Treating Lethal Cystic,Fibrosis Infections

occurring antimicrobial peptides such as LL-37 found in the lung fluid which form part of the body's innate immune system. These positively charged antimicrobial peptides are electrostatic attracted to the negatively charged membranes of bacteria. Once attached to the invaders' membranes, the antimicrobial peptides permeabilize and destroy the bacterial membranes leading to bacterial cell death. This highly effective mechanism of protecting the lung from bacterial infection does not work well in patients with cystic fibrosis as those patients have much higher levels of other negatively charged components in their sputum which bind to and inactivate the antimicrobial peptides. As a result, patients with cystic fibrosis are at high risk for lung infections throughout their lifetimes and the repeated bouts of lung infections scar the lung tissue and ultimately rob the patients of their ability to breathe.

"The conventional therapy used to treat Pseudomonas infections in cystic fibrosis patients is Tobramycin but there are an increasing number of Tobramycin resistant strains of Pseudomonas. There is an urgent need for the development of new antibiotics to treat these and other gram-negative bacterial infections," said Steven Porter, Chairman and CEO of Ceragenix Pharmaceuticals. "Our goal is to find a partner to help us advance development of this application."

About Ceragenix

Ceragenix Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops and commercializes novel anti-infective drugs based on its proprietary class of compounds, Ceragenins(TM) (or CSAs). Active against a broad range of gram positive and negative bacteria, these agents are being developed as anti-infective medical device coatings (Ceracides(TM)) and as therapeutics for antibiotic-resistant organisms. Ceragenix also owns exclusive rights to Barrier Repair Technology for the treatment of dermatological disorders including atopic dermatitis, neonatal skin disord
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Ceragenix Announces Results from Phase IV Study of EpiCeram Meet All Primary and Secondary Endpoints
2. Ceragenix Announces New Publication of Scientific Research on Ceragenin Technology
3. Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm Formation in 21 Day Study
4. Neurogen Proprietary Insomnia Compound Data for Two Studies Presented at Associated Professional Sleep Societies Annual Meeting
5. Neurogen Proprietary Insomnia Compound Data Presented at Associated Professional Sleep Societies Annual Meeting
6. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
7. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting
8. Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference
9. ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds for Solid Tumors Are to be Reported at ASCO
10. Neurogen Proprietary Insomnia Compound Data Presented at American Psychiatric Association Annual Meeting
11. Microbia Announces Positive Phase 2 Results for Its Investigational Compound Linaclotide
Post Your Comments:
(Date:12/24/2014)... /CNW/ -   The ... Canada tests confirmed it contains two undeclared amphetamine-like drug ... The distributor, Empire Health Distribution of Terrebonne, ... stores across Canada .  Jetfuel Superburn ... loss and increased energy. What consumers ...
(Date:12/24/2014)... Dec. 24, 2014  Actavis plc (NYSE: ... has received a complete response letter from the ... New Drug Application (NDA) for the fixed-dose combination ... of hypertension.   Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... in the receipt of a complete response letter, ...
(Date:12/24/2014)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... preliminary financial results for the first quarter of ... Ended September 30, 2014 Financial Highlights: , ... in 1Q14 with gross margins improved to 52% ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12
... OAKS, Calif., Nov. 5 Amgen (Nasdaq: AMGN ... trial evaluating Vectibix® (panitumumab) administered in combination with FOLFOX ... colorectal cancer (mCRC) failed to meet a secondary endpoint ... announced that the trial met its primary endpoint by ...
... YORK, Nov. 5 RF|Binder Partners today announced that ... Amex: CTT ) to help roll out and ... management medical device for treating high-intensity oncologic and neuropathic ... CTT is working to expand awareness of ...
Cached Medicine Technology:Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer 2Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer 3Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer 4Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer 5Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer 6Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer 7Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer 8Competitive Technologies Selects RF|Binder as Public Relations Agency of Record 2Competitive Technologies Selects RF|Binder as Public Relations Agency of Record 3
(Date:12/26/2014)... 26, 2014 It is said that nothing ... Today, UWDress.com, the famous wedding dress supplier, shows its ... site-wide cocktail gown promotion. , UWDress.com’s navy cocktail gowns ... they come in high fashion styles. Simple dresses in bright ... the occasion; they are specially designed for those who want ...
(Date:12/26/2014)... 2014 “Many people become overwhelmed by ... claim issues and phone calls with insurance companies,” The ... featuring their free eBook on pedestrian and bicycle ... pedestrian and bicycle auto accident claims assures the injured ... of professionally handling their case while they focus on ...
(Date:12/25/2014)... 2014 The microscopy market is ... to reach $5,756.0 million by 2019. Optical microscopy ... The electron microscopes product segment is expected to ... , Rising focus on nanotechnology, technological advancements, and ... microscopy market. , Get Full Copy of Report ...
(Date:12/25/2014)... December 25, 2014 Product liability lawsuits ... hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward ... an Order issued in the U.S. District Court, Northern ... convene an open conference on January 7, 2015, at ... Courthouse in West Palm Beach, Florida. The Conference is ...
(Date:12/25/2014)... 2014 Recently, BellasDress has ... its wedding dresses. BellasDress has chosen their best-selling lace ... choices for the holiday season. , Now, BellasDress.com ... wedding gowns here at discount prices. The business hopes ... its website. , “All our elegant products ...
Breaking Medicine News(10 mins):Health News:UWDress.com Shows Its New Navy Cocktail Dresses For 2015 2Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2
... Estes Audiology ... Roundup , ... 30, 2010 -- Estes Audiology and the Windcrest SERTOMA Club (San Antonio) ... Aid Roundup at Estes Audiology in New Braunfels on Tuesday, May 18, 2010 between 2:00-4:00. The ...
... other countries, CDC experts say , , FRIDAY, April 30 ... figures are available, about seven infants died for every 1,000 ... 2005 and the lowest infant death rate since 1995, U.S ... mortality was significant, the United States still ranks near the ...
... daily nasal washes , FRIDAY, April 30 (HealthDay News) -- ... a popular way to try to reduce allergy symptoms and ... that this simple treatment might also help prevent ear infections ... children who received an average of four nasal irrigations four ...
... protein ,fingerprints, in the blood of lung cancer patients ... whose tumors are more likely to shrink when treated ... are unavailable, according to new data presented at the ... Erlotinib is one of a class of drugs that ...
... to blame, study finds , FRIDAY, April 30 (HealthDay News) ... help explain why spouses of kidney dialysis patients are at ... study. , "We were surprised to find that the risk ... is just about as high as it is for blood ...
... political advocacy, study finds , FRIDAY, April 30 (HealthDay News) ... parents in their corner, with a new survey showing that ... of kids with the developmental disorder. , Grandparents are helping ... youngsters with autism. In fact, the report found that grandparents ...
Cached Medicine News:Health News:Estes Audiology and SERTOMA Club Windcrest Celebrate Better Hearing and Speech Month with Hearing Aid Roundup 2Health News:Estes Audiology and SERTOMA Club Windcrest Celebrate Better Hearing and Speech Month with Hearing Aid Roundup 3Health News:U.S. Infant Deaths on the Decline 2Health News:U.S. Infant Deaths on the Decline 3Health News:Nasal Saline Rinses Reduce Ear Infections in Kids 2Health News:Nasal Saline Rinses Reduce Ear Infections in Kids 3Health News:Blood test may identify lung cancer patients likely to respond to erlotinib 2Health News:Why Spouses of Dialysis Patients Get Kidney Disease Too 2Health News:Grandparents Play Vital Role for Autistic Children 2Health News:Grandparents Play Vital Role for Autistic Children 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: